STOCK TITAN
  1. Home
  2. News
  3. ONCY

Oncolytics Biotech, Inc. - ONCY STOCK NEWS

Welcome to our dedicated news page for Oncolytics Biotech (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oncolytics Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oncolytics Biotech's position in the market.

News
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
Rhea-AI Summary
Oncolytics Biotech® Inc. announces the acceptance of two abstracts at the 2024 American Society of Clinical Oncology Annual Meeting. The abstracts focus on pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma and blood TIL expansion in patients with pancreatic, breast, and colon cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Rhea-AI Summary
Oncolytics Biotech Inc. announces a Type C meeting request with the FDA for a registration-enabling trial in HR+/HER2- metastatic breast cancer. Positive results from the BRACELET-1 trial and upcoming overall survival data in H2 2024 indicate a transformative year ahead.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
none
-
News
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
Rhea-AI Summary
Oncolytics Biotech® Inc. President and CEO, Dr. Matt Coffey, will join the Viral Approaches in Oncology panel at Canaccord Genuity's Horizons in Oncology Virtual Conference on April 15, 2024. The company will also hold virtual investor meetings at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences
News
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Rhea-AI Summary
Oncolytics Biotech Inc. announces positive 2023 data, advancements in pancreatic cancer studies, and expansion of pelareorep potential in various cancer cohorts. The company reported impressive results from the GOBLET study in anal carcinoma and plans to initiate a registration-enabling study in pancreatic cancer in 2024. The cash position of $34.9 million provides financial stability through critical milestones into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
earnings
-
News
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
Rhea-AI Summary
Investorideas.com issues a sector snapshot on pancreatic cancer treatments, highlighting Oncolytics Biotech® Inc. The global pancreatic cancer market is projected to grow at a CAGR of 18% between 2024 and 2036, reaching a revenue of USD 36 billion by 2036.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none
-
News
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
Rhea-AI Summary
Oncolytics Biotech Inc. announces a new Phase 1/2 cohort study evaluating pelareorep in combination with modified FOLFIRINOX with and without atezolizumab in pancreatic cancer patients. The study, supported by a US$5 million grant from PanCAN, aims to broaden the use of pelareorep in PDAC patients. The company is optimistic about the potential of this novel treatment approach to improve patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.96%
Tags
none
News
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Rhea-AI Summary
Oncolytics Biotech Inc. to host a conference call and webcast on March 7, 2024, to discuss corporate update and financial results for Q4 and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.86%
Tags
conferences earnings
-
News
Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
Rhea-AI Summary
Oncolytics Biotech® Inc. announces CEO Dr. Matt Coffey will present at Cancer Advocacy Group of Louisiana's conference. The presentation will take place on March 1, 2024, at the Ritz Carlton Hotel in New Orleans, LA. Company management will also participate in investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
News
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
Rhea-AI Summary
Oncolytics Biotech® Inc. expands enrollment for anal cancer cohort in GOBLET study evaluating pelareorep in combination with atezolizumab, showcasing promising clinical data exceeding success criteria. The company aims to address the unmet medical needs in advanced anal cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
News
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
Rhea-AI Summary
Oncolytics Biotech® Inc. (NASDAQ: ONCY) announces positive Stage 1 data for pelareorep in combination with atezolizumab in anal cancer cohort of GOBLET study, showing a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response. The expansion of enrollment is supported by strong clinical data exceeding success criteria, potentially opening new treatment options for patients with advanced anal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
none
Stock ONCY logo
Oncolytics Biotech, Inc.

Nasdaq:ONCY

ONCY Rankings

#4425 Ranked by Market Cap
#846 Ranked by Stock Gains
N/A Ranked by Dividends

ONCY Stock Data

85.98M
66.96M
6.16%
6.88%
1.23%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Canada
Calgary

About ONCY

oncolytics biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. the company is conducting clinical studies using reolysin®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. oncolytics’ clinical program includes a number of human trials at a variety of stages including a phase iii trial in head and neck cancers. the company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.